Transcript:

Robert Ang | Chief Executive Officer | Vor Biopharma:
My company has created over 160 jobs in Massachusetts.

Jeb Keiper | Former Chief Executive Officer | Nimbus Therapeutics:
My company has created over 200 jobs in Boston.

Jay Duker | President & Chief Executive Officer | EyePoint Pharmaceuticals:
In the past year alone, my company has created over 70 new, well-paying jobs in Massachusetts.

Daphne Zohar | Founder & Chief Executive Officer | Seaport Therapeutics:
My current and previous companies have created thousands of jobs in Boston.

The Massachusetts economy is powered by over 117,000 biotech jobs, generating $23 billion in biotech wages.

Aoife Brennan | Chief Executive Officer | Climb Bio:
We're proud to be based in Massachusetts.

Chen Schor | President & Chief Executive Officer | Adicet Bio:
We're proud to be based in Boston.

ShiYin Foo | Chief Executive Officer | Arvada Therapeutics:
We're proud to be based in Boston.

Dan O'Connell I Board Member & Chief Executive Officer | Acumen Pharmaceuticals:
We're proud to be based in Massachusetts.

In 2023, MA biopharma companies accounted for 17% of the state's total employment growth.

Massachusetts companies are among the most innovative, driven, and impactful biotechs in the world.

Will West | Chief Executive Officer | CellCentric:
Many small biotech companies, including mine, are working on remarkable new technologies that we hope will someday allow us to better treat and even cure leukemias.

Dan O'Connell I Board Member & Chief Executive Officer | Acumen Pharmaceuticals:
Alzheimer's,

Jeb Keiper | Former Chief Executive Officer | Nimbus Therapeutics
colon cancer,

Mathai Mammen | Chairman & Chief Executive Officer | Parabilis Biopharmaceuticals:
pancreatic cancer,

ShiYin Foo | Chief Executive Officer | Arvada Therapeutics:
heart disease,

Chen Schor | President & Chief Executive Officer | Adicet Bio:
autoimmune diseases,

Jay Duker | President & Chief Executive Officer | EyePoint Pharmaceuticals:
blindness,

Mark Rus | Director & Chief Executive Officer | Delix Therapeutics:
depression,

Aoife Brennan | Chief Executive Officer | Climb Bio:
kidney diseases,

Sagar Vaidya | Chief Medical Officer | Cerevance:
Parkinson's disease.

Robert Ang | Chief Executive Officer | Vor Biopharma:
And there's a good chance you are helping us. Here's how:

Joel Barrish | Chief Executive Officer | Avilar Therapeutics:
If you're saving for retirement, as millions of working Americans are, there's a good chance some of your savings is invested in biotechnology,

Kristina Masson | Co-Founder & Executive Vice President | Acrivon Therapeutics:
and maybe even indirectly in my company.

Jay Duker | President & Chief Executive Officer | EyePoint Pharmaceuticals:
So thank you.

In 2024, more than 1000 biotech companies in Massachusetts drew $7.9 billion in VC funding to search for new treatments and cures.

Blake Aftab | Chief Science Officer | Adicet Bio:
Unfortunately, some people, including some members of Congress, think that the way to help patients afford treatment is by letting the government control the prices of novel medicines.

Those calling for price controls that would lower biotech investment include representatives of our state.

Mathai Mammen | Chairman & Chief Executive Officer | Parabilis Biopharmaceuticals:
The problem is that price controls drive investors away. That's the case not only in biotechnology but in any industry.

Our representatives should work to fix the IRA "pill penalty," NOT add more price controls.

ShiYin Foo | Chief Executive Officer | Arvada Therapeutics:
And price controls on novel medicines won't even save America money, because what's special about medicines is that they go generic.

Sagar Vaidya | Chief Medical Officer | Cerevance:
Novel medicines are branded until their patents expire. After that, they drop in price and cost America very little, but they still keep us healthy and out of the hospitals.

Joel Barrish | Chief Executive Officer | Avilar Therapeutics:
So let's hope that Congress does not resort to price controls that turn investors away from research like ours,

Mark Rus | Director & Chief Executive Officer | Delix Therapeutics:
but instead caps out-of-pocket costs for patients.

Our leaders should advocate for insurance reform that delivers first-dollar coverage and insurance with low out-of-pocket costs.

Kristina Masson | Co-Founder & Executive Vice President | Acrivon Therapeutics:
Insurance reform is the solution that will allow all of us by investing, paying premiums, and doing science to create new, affordable medicines together.

Jeb Keiper | Former Chief Executive Officer | Nimbus Therapeutics:
Thank you for your support for helping to make breakthroughs by companies like ours possible.

James McArthur | Board Member & Chief Executive Officer | PepGen Inc.:
Thank you for helping us strive to bring new treatments to people who desperately need them.

Charlotte McKee | Chief Medical Officer | Sionna Therapeutics:
And thank you for being part of this massive team effort to bring a healthier, happier, more productive future.

Jay Duker | President & Chief Executive Officer | EyePoint Pharmaceuticals:
And every time you check your retirement account or see that insurance deduction on your paycheck, we hope you don't just see numbers, but the promise of scientific progress.

Will West | Chief Executive Officer | CellCentric:
We hope that you will see a brighter, healthier future that you are helping to build.

Let's hope the representatives we send to Washington ...
protect the Massachusetts biotech jobs that protect us all.